Epsin-mediated degradation of IP3R1 fuels atherosclerosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 08 2020
Historique:
received: 26 08 2019
accepted: 15 07 2020
entrez: 10 8 2020
pubmed: 10 8 2020
medline: 10 9 2020
Statut: epublish

Résumé

The epsin family of endocytic adapter proteins are widely expressed, and interact with both proteins and lipids to regulate a variety of cell functions. However, the role of epsins in atherosclerosis is poorly understood. Here, we show that deletion of endothelial epsin proteins reduces inflammation and attenuates atherosclerosis using both cell culture and mouse models of this disease. In atherogenic cholesterol-treated murine aortic endothelial cells, epsins interact with the ubiquitinated endoplasmic reticulum protein inositol 1,4,5-trisphosphate receptor type 1 (IP3R1), which triggers proteasomal degradation of this calcium release channel. Epsins potentiate its degradation via this interaction. Genetic reduction of endothelial IP3R1 accelerates atherosclerosis, whereas deletion of endothelial epsins stabilizes IP3R1 and mitigates inflammation. Reduction of IP3R1 in epsin-deficient mice restores atherosclerotic progression. Taken together, epsin-mediated degradation of IP3R1 represents a previously undiscovered biological role for epsin proteins and may provide new therapeutic targets for the treatment of atherosclerosis and other diseases.

Identifiants

pubmed: 32770009
doi: 10.1038/s41467-020-17848-4
pii: 10.1038/s41467-020-17848-4
pmc: PMC7414107
doi:

Substances chimiques

Adaptor Proteins, Vesicular Transport 0
Inositol 1,4,5-Trisphosphate Receptors 0
epsin 0
Cholesterol 97C5T2UQ7J
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3984

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL133216
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146134
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL093242
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL145241
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL158097
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL134633
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141858
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141853
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137229
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118676
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130845
Pays : United States

Références

Singh, R. B., Mengi, S. A., Xu, Y. J., Arneja, A. S. & Dhalla, N. S. Pathogenesis of atherosclerosis: a multifactorial process. Exp. Clin. Cardiol.7, 40–53 (2002).
pubmed: 19644578 pmcid: 2716189
Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol.15, 104–116 (2015).
pubmed: 25614320 pmcid: 4669071
Deanfield, J. E., Halcox, J. P. & Rabelink, T. J. Endothelial function and dysfunction: testing and clinical relevance. Circulation115, 1285–1295 (2007).
pubmed: 17353456
Libby, P. Inflammation in atherosclerosis. Arterioscler Thromb. Vasc. Biol.32, 2045–2051 (2012).
pubmed: 22895665 pmcid: 3422754
Moore, K. J., Sheedy, F. J. & Fisher, E. A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol.13, 709–721 (2013).
pubmed: 23995626 pmcid: 4357520
Galkina, E. et al. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J. Exp. Med.203, 1273–1282 (2006).
pubmed: 16682495 pmcid: 2121208
Schwartz, C. J., Valente, A. J., Sprague, E. A., Kelley, J. L. & Nerem, R. M. The pathogenesis of atherosclerosis: an overview. Clin. Cardiol.14, I1–I16 (1991).
pubmed: 2044253
Gimbrone, M. A. Jr. & Garcia-Cardena, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res.118, 620–636 (2016).
pubmed: 26892962 pmcid: 4762052
Desideri, G. & Ferri, C. Endothelial activation. Sliding door to atherosclerosis. Curr. Pharm. Des.11, 2163–2175 (2005).
pubmed: 16026286
Tousoulis, D., Charakida, M. & Stefanadis, C. Endothelial function and inflammation in coronary artery disease. Heart92, 441–444 (2006).
pubmed: 16159981
Chen, H., Slepnev, V. I., Di Fiore, P. P. & De Camilli, P. The interaction of epsin and Eps15 with the clathrin adaptor AP-2 is inhibited by mitotic phosphorylation and enhanced by stimulation-dependent dephosphorylation in nerve terminals. J. Biol. Chem.274, 3257–3260 (1999).
pubmed: 9920862
Chen, H. et al. Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis. Nature394, 793–797 (1998).
pubmed: 9723620
Chen, H. & De Camilli, P. The association of epsin with ubiquitinated cargo along the endocytic pathway is negatively regulated by its interaction with clathrin. Proc. Natl Acad. Sci. USA102, 2766–2771 (2005).
pubmed: 15701696
Ford, M. G. et al. Curvature of clathrin-coated pits driven by epsin. Nature419, 361–366 (2002).
pubmed: 12353027
Wendland, B. Epsins: adaptors in endocytosis? Nat. Rev. Mol. Cell Biol.3, 971–977 (2002).
pubmed: 12461563
Messa, M. et al. Epsin deficiency impairs endocytosis by stalling the actin-dependent invagination of endocytic clathrin-coated pits. eLife3, e03311 (2014).
pubmed: 25122462 pmcid: 4161027
Ko, G. et al. Selective high-level expression of epsin 3 in gastric parietal cells, where it is localized at endocytic sites of apical canaliculi. Proc. Natl Acad. Sci. USA107, 21511–21516 (2010).
pubmed: 21115825
Pasula, S. et al. Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. J. Clin. Invest.122, 4424–4438 (2012).
pubmed: 23187125 pmcid: 3533553
Chen, H. et al. Embryonic arrest at midgestation and disruption of Notch signaling produced by the absence of both epsin 1 and epsin 2 in mice. Proc. Natl Acad. Sci. USA106, 13838–13843 (2009).
pubmed: 19666558
Chang, B. et al. Epsin is required for Dishevelled stability and Wnt signalling activation in colon cancer development. Nat. Commun.6, 6380 (2015).
pubmed: 25871009 pmcid: 4397653
Tessneer, K. L. et al. Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression. ISRN Oncol.2013, 420597 (2013).
pubmed: 23691361 pmcid: 3649151
Brophy, M. L. et al. Myeloid-specific deletion of epsins 1 and 2 reduces atherosclerosis by preventing LRP-1 downregulation. Circ. Res.124, e6–e19 (2019).
pubmed: 30595089 pmcid: 6375743
Foskett, J. K., White, C., Cheung, K. H. & Mak, D. O. Inositol trisphosphate receptor Ca2+ release channels. Physiol. Rev.87, 593–658 (2007).
pubmed: 17429043 pmcid: 2901638
Geovanini, G. R. & Libby, P. Atherosclerosis and inflammation: overview and updates. Clin. Sci.132, 1243–1252 (2018).
pubmed: 29930142
Zhang, S. H., Reddick, R. L., Piedrahita, J. A. & Maeda, N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science258, 468–471 (1992).
pubmed: 1411543
Hotamisligil, G. S. Endoplasmic reticulum stress and atherosclerosis. Nat. Med.16, 396–399 (2010).
pubmed: 20376052 pmcid: 2897068
Minamino, T. & Kitakaze, M. ER stress in cardiovascular disease. J. Mol. Cell Cardiol.48, 1105–1110 (2010).
pubmed: 19913545
Massaeli, H., Austria, J. A. & Pierce, G. N. Chronic exposure of smooth muscle cells to minimally oxidized LDL results in depressed inositol 1,4,5-trisphosphate receptor density and Ca(2+) transients. Circ. Res.85, 515–523 (1999).
pubmed: 10488054
Ewart, M. A. et al. Changes in IP3 receptor expression and function in aortic smooth muscle of atherosclerotic mice. J. Vasc. Res54, 68–78 (2017).
pubmed: 28365690 pmcid: 5804831
Lu, J. P., Wang, Y., Sliter, D. A., Pearce, M. M. & Wojcikiewicz, R. J. RNF170 protein, an endoplasmic reticulum membrane ubiquitin ligase, mediates inositol 1,4,5-trisphosphate receptor ubiquitination and degradation. J. Biol. Chem.286, 24426–24433 (2011).
pubmed: 21610068 pmcid: 3129221
Wright, F. A. & Wojcikiewicz, R. J. Chapter 4-inositol 1,4,5-trisphosphate receptor ubiquitination. Prog. Mol. Biol. Transl. Sci.141, 141–159 (2016).
pubmed: 27378757
Zhong, H., Huang, X. & Doller, D. Multiplexing label-free and fluorescence-based methods for pharmacological characterization of GPCR ligands. In Label-Free Biosensor Methods in Drug Discovery (ed. Fang, Y.) 215–231 (Springer, New York, 2015).
Higo, T. et al. Mechanism of ER stress-induced brain damage by IP(3) receptor. Neuron68, 865–878 (2010).
pubmed: 21145001
Walpola, P. L., Gotlieb, A. I., Cybulsky, M. I. & Langille, B. L. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler Thromb. Vasc. Biol.15, 2–10 (1995).
pubmed: 7538423
Cybulsky, M. I. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest107, 1255–1262 (2001).
pubmed: 11375415 pmcid: 209298
Arruda, A. P. & Hotamisligil, G. S. Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes. Cell Metab.22, 381–397 (2015).
pubmed: 26190652 pmcid: 4558313
Dong, Y. et al. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation121, 792–803 (2010).
pubmed: 20124121 pmcid: 2825900
Yuan, Q. et al. Maintenance of normal blood pressure is dependent on IP3R1-mediated regulation of eNOS. Proc. Natl Acad. Sci. USA113, 8532–8537 (2016).
pubmed: 27402766
Ouyang, K. et al. Loss of IP3R-dependent Ca2+ signalling in thymocytes leads to aberrant development and acute lymphoblastic leukemia. Nat. Commun.5, 4814 (2014).
pubmed: 25215520 pmcid: 5537137
Dong, R. et al. Endosome-ER contacts control actin nucleation and retromer function through VAP-dependent regulation of PI4P. Cell166, 408–423 (2016).
pubmed: 27419871 pmcid: 4963242
Chung, J. et al. Intracellular transport. PI4P/phosphatidylserine countertransport at ORP5- and ORP8-mediated ER-plasma membrane contacts. Science349, 428–432 (2015).
pubmed: 26206935 pmcid: 4638224
Stathopulos, P. B. et al. Themes and variations in ER/SR calcium release channels: structure and function. Physiology27, 331–342 (2012).
pubmed: 23223627
Brodsky, J. L. & Wojcikiewicz, R. J. Substrate-specific mediators of ER associated degradation (ERAD). Curr. Opin. Cell Biol.21, 516–521 (2009).
pubmed: 19443192 pmcid: 2756615
Wojcikiewicz, R. J., Pearce, M. M., Sliter, D. A. & Wang, Y. When worlds collide: IP(3) receptors and the ERAD pathway. Cell Calcium46, 147–153 (2009).
pubmed: 19709743 pmcid: 2752845
Oberdorf, J., Webster, J. M., Zhu, C. C., Luo, S. G. & Wojcikiewicz, R. J. Down-regulation of types I, II and III inositol 1,4,5-trisphosphate receptors is mediated by the ubiquitin/proteasome pathway. Biochem J.339(Pt 2), 453–461 (1999).
pubmed: 10191279 pmcid: 1220177
Lin, Q. et al. Inositol 1,4,5-trisphosphate receptors in endothelial cells play an essential role in vasodilation and blood pressure regulation. J. Am. Heart Assoc.8, e011704 (2019).
pubmed: 30755057 pmcid: 6405661
Lin, Q. et al. IP3 receptors regulate vascular smooth muscle contractility and hypertension. JCI Insight1, e89402 (2016).
pubmed: 27777977 pmcid: 5070959
He, M. et al. Atheroprotective flow upregulates ITPR3 (Inositol 1,4,5-Trisphosphate Receptor 3) in vascular endothelium via KLF4 (Kruppel-Like Factor 4)-mediated histone modifications. Arterioscler Thromb. Vasc. Biol.39, 902–914 (2019).
pubmed: 30917677 pmcid: 6536300
Martin-Garrido, A. et al. Hydrogen peroxide down-regulates inositol 1,4,5-trisphosphate receptor content through proteasome activation. Free Radic. Biol. Med.47, 1362–1370 (2009).
pubmed: 19596064
Sliter, D. A. et al. Mass spectrometric analysis of type 1 inositol 1,4,5-trisphosphate receptor ubiquitination. J. Biol. Chem.283, 35319–35328 (2008).
pubmed: 18955483 pmcid: 2602886
Rahman, H. A. et al. Selective targeting of a novel epsin-VEGFR2 interaction promotes VEGF-mediated angiogenesis. Circ. Res.118, 957–969 (2016).
pubmed: 26879230 pmcid: 4798882
Dong, Y. et al. Motif mimetic of epsin perturbs tumor growth and metastasis. J. Clin. Invest.125, 4349–4364 (2015).
pubmed: 26571402 pmcid: 4665789
Que, X. et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature558, 301–306 (2018).
pubmed: 29875409 pmcid: 6033669
Bezprozvanny, I. Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington’s disease and spinocerebellar ataxias. Neurochem. Res.36, 1186–1197 (2011).
pubmed: 21210219 pmcid: 3094593
Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature551, 92–94 (2017).
pubmed: 29059683 pmcid: 5798588
Parmar, P. G. et al. International Genome-Wide Association Study Consortium identifies novel loci associated with blood pressure in children and adolescents. Circ. Cardiovasc. Genet.9, 266–278 (2016).
pubmed: 26969751 pmcid: 5279885
Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med.17, 1410–1422 (2011).
pubmed: 22064431
Wu, H. et al. Epsin deficiency promotes lymphangiogenesis through regulation of VEGFR3 degradation in diabetes. J. Clin. Invest.128, 4025–4043 (2018).
pubmed: 30102256 pmcid: 6118634
Wang, J. M., Chen, A. F. & Zhang, K. Isolation and primary culture of mouse aortic endothelial cells. J. Vis. Exp.118, e52965 (2016).
Kawashima, Y. et al. Enhanced recovery of lyophilized peptides in shotgun proteomics by using an LC-ESI-MS compatible surfactant. Proteomics13, 751–755 (2013).
pubmed: 23300112
Keller, A., Nesvizhskii, A. I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem.74, 5383–5392 (2002).
pubmed: 12403597
Nesvizhskii, A. I., Keller, A., Kolker, E. & Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem.75, 4646–4658 (2003).
pubmed: 14632076
Zhu, W., Smith, J. W. & Huang, C. M. Mass spectrometry-based label-free quantitative proteomics. J. Biomed. Biotechnol.2010, 840518 (2010).
pubmed: 19911078
Yago, T. et al. Blocking neutrophil integrin activation prevents ischemia-reperfusion injury. J. Exp. Med.212, 1267–1281 (2015).
pubmed: 26169939 pmcid: 4516797
Yao, L. et al. Elevated CXCL1 expression in gp130-deficient endothelial cells impairs neutrophil migration in mice. Blood122, 3832–3842 (2013).
pubmed: 24081661 pmcid: 3843240
Kawakami, A. et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation114, 681–687 (2006).
pubmed: 16894036
Cui, K. et al. Inhibition of integrin alphaDbeta2-mediated macrophage adhesion to end product of docosahexaenoic acid (DHA) oxidation prevents macrophage accumulation during inflammation. J. Biol. Chem.294, 14370–14382 (2019).
pubmed: 31395659
Dong, Y. et al. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes59, 1386–1396 (2010).
pubmed: 20299472 pmcid: 2874699
Chakraborty, S. et al. Lipopolysaccharide modulates neutrophil recruitment and macrophage polarization on lymphatic vessels and impairs lymphatic function in rat mesentery. Am. J. Physiol. Heart Circ. Physiol.309, H2042–H2057 (2015).
pubmed: 26453331 pmcid: 4698422
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods9, 671–675 (2012).
pubmed: 5554542 pmcid: 5554542
Lee, Y., Fluckey, J. D., Chakraborty, S. & Muthuchamy, M. Hyperglycemia- and hyperinsulinemia-induced insulin resistance causes alterations in cellular bioenergetics and activation of inflammatory signaling in lymphatic muscle. FASEB J.31, 2744–2759 (2017).
pubmed: 28298335 pmcid: 5471512
Chiu, J. J. & Chien, S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol. Rev.91, 327–387 (2011).
pubmed: 21248169
Bischoff, J. et al. CD45 expression in mitral valve endothelial cells after myocardial infarction. Circ. Res.119, 1215–1225 (2016).
pubmed: 27750208 pmcid: 5215059
He, C. et al. PDGFRbeta signalling regulates local inflammation and synergizes with hypercholesterolaemia to promote atherosclerosis. Nat. Commun.6, 7770 (2015).
pubmed: 26183159 pmcid: 4507293
Schulman, J. J., Wright, F. A., Kaufmann, T. & Wojcikiewicz, R. J. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage. J. Biol. Chem.288, 25340–25349 (2013).
pubmed: 23884412 pmcid: 3757198
Tessneer, K. L. et al. Genetic reduction of vascular endothelial growth factor receptor 2 rescues aberrant angiogenesis caused by epsin deficiency. Arterioscler. Thromb. Vasc. Biol.34, 331–337 (2014).
pubmed: 24311377
Rajamaki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE5, e11765 (2010).
pubmed: 20668705 pmcid: 2909263

Auteurs

Yunzhou Dong (Y)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Yang Lee (Y)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Kui Cui (K)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Ming He (M)

Department of Medicine, University of California, San Diego, San Diego, CA, 92093, USA.

Beibei Wang (B)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Sudarshan Bhattacharjee (S)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Bo Zhu (B)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Tadayuki Yago (T)

Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.

Kun Zhang (K)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Lin Deng (L)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.

Kunfu Ouyang (K)

Department of Medicine, University of California, San Diego, San Diego, CA, 92093, USA.

Aiyun Wen (A)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Douglas B Cowan (DB)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Kai Song (K)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Lili Yu (L)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Megan L Brophy (ML)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Xiaolei Liu (X)

Center for Vascular and Developmental Biology, Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Chicago, IL, 60611, USA.

Jill Wylie-Sears (J)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Hao Wu (H)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Scott Wong (S)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Guanglin Cui (G)

Department of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Yusuke Kawashima (Y)

Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Center for Disease Proteomics, Kitasato University School of Science, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.

Hiroyuki Matsumoto (H)

Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Yoshio Kodera (Y)

Center for Disease Proteomics, Kitasato University School of Science, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.

Richard J H Wojcikiewicz (RJH)

Department of Pharmacology, SUNY Upstate Medical University, Syracuse, NY, 13210, USA.

Sanjay Srivastava (S)

Department of Medicine, Division of Cardiovascular Medicine, University of Louisville School of Medicine, Louisville, KY, 40202, USA.

Joyce Bischoff (J)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Da-Zhi Wang (DZ)

Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Klaus Ley (K)

La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA.

Hong Chen (H)

Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. hong.chen@childrens.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH